Results 21 to 30 of about 155,597 (349)

Therapeutic Approach for Trigeminal Neuralgia: A Systematic Review

open access: yesBiomedicines, 2023
This umbrella review aimed to determine the various drugs used to treat trigeminal neuralgia (TN) and to evaluate their efficacies as well as side effects by surveying previously published reviews. An online search was conducted using PubMed, CRD, EBSCO,
Muhammad Haseeb Rana   +10 more
doaj   +1 more source

Evaluation of the Effect of (S)-3,4-Dicarboxyphenylglycine as a Metabotropic Glutamate Receptors Subtype 8 Agonist on Thermal Nociception Following Central Neuropathic Pain [PDF]

open access: yesAsian Spine Journal, 2021
Study Design In this study, we decided to change the activity of periaqueductal gray (PAG)'s metabotropic glutamate receptors subtype 8 (mGluR8) by means of its specific agonist, (S)-3,4-dicarboxyphenylglycine (DCPG), and by knock downing it with mGluR8 ...
Marjan Hosseini   +3 more
doaj   +1 more source

Contemporary management of pain in cirrhosis: Toward precision therapy for pain

open access: yesHepatology, EarlyView., 2022
Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman   +4 more
wiley   +1 more source

[EXPRESS] Trigeminal Neuralgia: an overview from pathophysiology to pharmacological treatments.

open access: yesMolecular Pain, 2020
The trigeminal nerve (V) is the fifth and largest of all cranial nerves and it is responsible for detecting sensory stimuli that arise from the craniofacial area.
Eder Gambeta   +2 more
semanticscholar   +1 more source

Trigeminal neuralgia as the sole neurological manifestation of COVID‐19: A case report

open access: yesHeadache, 2021
To describe a case report of trigeminal neuralgia (TN) due to coronavirus disease‐2019 (COVID‐19).
J. Molina-Gil   +2 more
semanticscholar   +1 more source

Percutaneous radiofrequency rhizotomy and neurovascular decompression of the trigeminal nerve for the treatment of facial pain Rizotomia percutânea por radiofreqüência e a descompressão neurovascular do nervo trigêmeo no tratamento das algias faciais

open access: yesArquivos de Neuro-Psiquiatria, 2006
OBJECTIVE: To determine the outcomes of 354 radiofrequency rhizotomies and 21 neurovascular decompressions performed as treatment for 367 facial pain patients (290 idiopathic trigeminal neuralgia, 52 symptomatic trigeminal neuralgia, 16 atypical facial ...
Manoel J. Teixeira   +2 more
doaj   +1 more source

Aetiology of Headache: A Prospective Observational Study from Southern India [PDF]

open access: yesJournal of Clinical and Diagnostic Research
Introduction: Headache is a widely prevalent symptom that greatly affects the quality of life. Yet, the disability caused by headache disorders does not receive the attention it deserves.
B Naveen Kumar   +1 more
doaj   +1 more source

Combination of pharmacotherapy and lidocaine analgesic block of the peripheral trigeminal branches for trigeminal neuralgia: a pilot study [PDF]

open access: yes, 2015
Classical trigeminal neuralgia (CTN) is treated predominantly by pharmacotherapy but side effects and unsuccessful occurs. The current study was carried out to evaluate the therapeutic effect of combination of pharmacotherapy and lidocaine block ...
Bruti, Gianluca   +9 more
core   +3 more sources

Trigeminal Neuralgia: Basic and Clinical Aspects

open access: yesCurrent Neuropharmacology, 2020
The trigeminal nerve is the largest of all cranial nerves. It has three branches that provide the main sensory innervation of the anterior two-thirds of the head and face.
E. Araya   +3 more
semanticscholar   +1 more source

Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: The trigeminal neuralgia experience [PDF]

open access: yes, 2018
Background: This study aimed to describe recruitment challenges encountered during a phase IIa study of vixotrigine, a state and use-dependent Nav1.7 channel blocker, in individuals with trigeminal neuralgia.
Bendtsen, Lars   +10 more
core   +4 more sources

Home - About - Disclaimer - Privacy